RT Journal Article
SR Electronic
T1 Associations between SARS-CoV-2 variants and risk of COVID-19 hospitalization among confirmed cases in Washington State: a retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.29.21264272
DO 10.1101/2021.09.29.21264272
A1 Paredes, Miguel I.
A1 Lunn, Stephanie M.
A1 Famulare, Michael
A1 Frisbie, Lauren A.
A1 Painter, Ian
A1 Burstein, Roy
A1 Roychoudhury, Pavitra
A1 Xie, Hong
A1 Mohamed Bakhash, Shah A.
A1 Perez, Ricardo
A1 Lukes, Maria
A1 Ellis, Sean
A1 Sathees, Saraswathi
A1 Mathias, Patrick C.
A1 Greninger, Alexander
A1 Starita, Lea M.
A1 Frazar, Chris D.
A1 Ryke, Erica
A1 Zhong, Weizhi
A1 Gamboa, Luis
A1 Threlkeld, Machiko
A1 Lee, Jover
A1 Nickerson, Deborah A.
A1 Bates, Daniel L.
A1 Hartman, Matthew E.
A1 Haugen, Eric
A1 Nguyen, Truong N.
A1 Richards, Joshua D.
A1 Rodriguez, Jacob L.
A1 Stamatoyannopoulos, John A.
A1 Thorland, Eric
A1 Melly, Geoff
A1 Dykema, Philip E.
A1 MacKellar, Drew C.
A1 Gray, Hannah K.
A1 Singh, Avi
A1 Peterson, JohnAric MoonDance
A1 Russell, Denny
A1 Torres, Laura Marcela
A1 Lindquist, Scott
A1 Bedford, Trevor
A1 Allen, Krisandra J.
A1 Oltean, Hanna N.
YR 2021
UL http://medrxiv.org/content/early/2021/10/27/2021.09.29.21264272.abstract
AB Background The COVID-19 pandemic is now dominated by variant lineages; the resulting impact on disease severity remains unclear. Using a retrospective cohort study, we assessed the risk of hospitalization following infection with nine variants of concern or interest (VOC/VOI).Methods Our study includes individuals with positive SARS-CoV-2 RT-PCR in the Washington Disease Reporting System and with available viral genome data, from December 1, 2020 to July 30, 2021. The main analysis was restricted to cases with specimens collected through sentinel surveillance. Using a Cox proportional hazards model with mixed effects, we estimated hazard ratios (HR) for the risk of hospitalization following infection with a VOC/VOI, adjusting for age, sex, and vaccination status.Findings Of the 23,563 cases, 22,068 (93.7%) were sequenced through sentinel surveillance, of which 582 (2.6%) were hospitalized due to COVID-19. Higher hospitalization risk was found for infections with Gamma (HR 3.23, 95% CI 2.19-4.76), Beta (HR 3.03, 95% CI 1.68-5.47), Delta (HR 2.35, 95% CI 1.72-3.22), and Alpha (HR 1.61, 95% CI 1.28-2.03) compared to infections with an ancestral lineage. Following VOC infection, unvaccinated patients show a similar higher hospitalization risk, while vaccinated patients show no significant difference in risk, both when compared to unvaccinated, ancestral lineage cases.Interpretation Infection with a VOC results in a higher hospitalization risk, with an active vaccination attenuating that risk. Our findings support promoting hospital preparedness, vaccination, and robust genomic surveillance.Competing Interest StatementALG reports funding for central testing lab from Abbott and research funding from Merck and Gilead. All other authors declare no competing interests.Funding StatementT.B. is a Pew Biomedical Scholar and is supported by NIH grant no. R35 GM119774, P.R. is supported by a CFAR New Investigator Award (NIH AI027757). The Seattle Flu Study is run through the Brotman Baty Institute for Precision Medicine and funded by Gates Ventures, the private office of Bill Gates. This work was supported by CDC BAA contract 75D30121C10982. Employees of the Institute for Disease Modeling (MF, RB) received no specific funding for the project. Computational analyses for UW Virology data were supported by Fred Hutch Scientific Computing (NIH ORIP grant S10OD028685). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Washington State Institutional Review Board designated this study as exempt. Sequencing and analysis of samples from the Seattle Flu Study was approved by the Institutional Review Board (IRB) at the University of Washington (protocol STUDY00006181). Sequencing of remnant clinical specimens at UW Virology Lab was approved by the University of Washington Institutional Review Board (protocol STUDY00000408). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests to access these data are handled by the Washington Department of Health